QuantiFERON-TB-GOLD In-Tube in patients with sarcoidosis

Abstract

Introduction: Sarcoidosis and tuberculosis (TB) are the diseases that share many similarities. Mycobacterium tuberculosis (MTB) culture results are the gold standard for the diagnosis of TB, but false positive results are not rare. The aim was to evaluate the utility of QFT in detecting latent TB infection in a group of sarcoidosis patients with negative history of TB and negative culture/BACTEC results, and checking sarcoidosis activity influence on the QFT results. Additionally, we assessed if QFT negative result may strengthen the suspicion that positive culture/BACTEC results are false positive.

Material and methods: 37 culture-negative and 6 culture-positive sarcoidosis patients were enrolled. On the basis of clinical and radiological data TB was considered unlikely (false-positive results). A control group consisted of age-matched subjects with excluded TB (n = 37). QuantiFERON-TB GOLD In-Tube (QIAGEN, USA) was used according to the manual. Test validity was checked basing on the results obtained from a low-risk (n = 21) and active TB group (n = 23).

Results: The frequency of positive results tended to be higher in MTB(−) sarcoidosis (24.3% vs. 13.5% for the control group, \( p = 0.37 \)), but was similar to the general population. None of culture-positive sarcoidosis patients was QFT-positive. The positive results were equally distributed among patients with active and inactive sarcoidosis.

Conclusions: QFT has been found to be the useful test for the detection of latent TB infection in sarcoidosis patients. Additionally, we confirm that sarcoidosis activity does not negatively influence the result of QFT. Moreover, QFT would be proposed as a cost-saving diagnostic test providing additional diagnostic information when false positive MTB culture result in the sarcoidosis patient is highly suspected. However, in each case clinical, radiological and epidemiological data should be considered before taking the therapeutic decision.

Key words: IGRA, quantiferon test, sarcoidosis, tuberculosis

Introduction

Sarcoidosis and tuberculosis (TB) are the diseases that share many similarities responsible for difficulties in differential diagnosis. *Mycobacterium tuberculosis* (MTB) antigens have been suspected to induce sarcoidosis [1], and the coexistence of both entities seems to be possible [2]. The recent molecular studies have also revealed that the diseases have similar blood transcriptional signature [3, 4]. That is why, intriguing hypothesis of sarcoidosis and tuberculosis as the two ends of the same disease spectrum has been proposed [5].

Clear-cut differential diagnosis may be critical in a clinical setting, as misdiagnosis or oversight of TB potentially brings serious epidemiological threat. The gold standard for TB recognition is the positive culture result for MTB, however, negative sputum results do not exclude the disease. Moreover, false positive results are not infrequent, and have been reported even in reference laboratories [6].

The tuberculin skin test (TST) — negative in almost all sarcoidosis patients due to the peripheral anergy — is not a valuable tool for detecting latent TB infection in these patients, however, positive results in active sarcoidosis strongly
suggest coexistent TB [7]. In vitro IFN-gamma release assays (IGRAs), which have been developed in the last decade, are considered most accurate for detection of latent TB infection (LTBI) [8]. An alternative to TST, but with higher specificity and sensitivity, these tests identify individuals infected with MTB, and are of great importance in BCG-vaccinated population, like the Polish one. Upon the stimulation with mixture of antigens: early secretory antigenic target 6 (ESAT-6), culture filtrate protein 10 (CFP-10) and TB7.7, QuantiFERON-TB Gold In-Tube test measures IFN-gamma concentration by the use of ELISA. It is of note however, that this commercial test does not discriminate between patients with LTBI and those with active disease [9, 10].

The results of already published studies into the use of IGRA tests in the diagnosis of latent TB infection in sarcoidosis patients are not fully conclusive [11–13]. Although the authors are concordant as to the fact that positive results are not more frequent than in non-sarcoidosis control subjects, none of these studies provided data on sarcoidosis patients with suspected coexistent tuberculosis on the basis of positive culture results. Besides, data on the influence of the activity of sarcoidosis and consequent peripheral depletion of T cells on the final result of IGRA test are also scarce.

Therefore, questions to be addressed in the present study are the following: 1) What is the utility of QFT in detecting latent TB infection in a group of sarcoidosis patients with negative history of TB and negative culture/BACTEC results? 2) Does sarcoidosis activity influence the QFT results? 3) Can QFT negative result strengthen the suspicion that positive culture/BACTEC results are false positive?

Material and methods

Study groups

Sarcoidosis — The MTB true negative

Consecutive 37 patients admitted to the Department for the confirmation of sarcoidosis, and in whom the diagnosis was confirmed according to international guidelines [14] were included. In all patients, diagnostic bronchoscopy did not reveal MTB, neither in smear nor in culture examination. The previous treatment of TB or contact with a person known to have active infection were the exclusion criteria. This was assessed by a dedicated self-prepared questionnaire, and negative answers were required to all the questions below: Have you ever been told by a doctor to have TB? Have you ever been treated for TB? Have you ever been suspected of TB? Have you ever had any contacts with someone known to suffer from TB? This subgroup will be further indicated as SarcMTB(true−). MTB in these patients was considered highly improbable, mainly due to inconsistent clinical (patients 2, 4, 5 with acute onset sarcoidosis), and radiological presentations (patients 1, 2, 4, 5 with no signs of parenchymal involvement, only enlarged hilar bilateral lymph nodes). A follow-up evaluation also revealed inconsistent reaction to anti-TB treatment (progression despite treatment in patients 3 and 6) or to the absence of treatment (full recovery in patients 1 and 4, despite lack of anti-TB treatment). Four patients were treated with anti-TB drugs (isoniazid 5 mg/kg, rifampicin 10 mg/kg (no more than 0.6 g/day), pyrazinamide 25 mg/kg and ethambutol 15 mg/kg): patients 3 and 6 due to progressive parenchymal changes associated with positive culture results and the patient 5 with very low probability of TB infection but due to high potential epidemiological threat (primary school teacher), and in the patient 2 also with very low TB probability, the decision was made by a pulmonologist from another institution. In four patients, oral prednisone (initially 0.5 mg/kg) was introduced after the diagnosis of sarcoidosis had been established (patients 1, 2, 3 and 6), but before blood sample for QFT was taken. The demographic and clinical data are provided in Table 1, and the detailed characteristics of S_MTB(true−) Patients in Table 2.
Table 1. Characteristics of the study group consisted of sarcoidosis patients with negative culture/BACTEC results (SarcMTB(–) group) and sarcoidosis with positive culture/BACTEC results (SarcMTB(false+) group)

<table>
<thead>
<tr>
<th>Group</th>
<th>Age (years) mean (SD)</th>
<th>Gender</th>
<th>Initial X-ray stage at onset</th>
<th>LS at onset</th>
<th>Active disease at V(0)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SarcMTB(–) (n = 37)</td>
<td>44 (11)</td>
<td>F — 13 (35%)</td>
<td>II — 16 (43%)</td>
<td>12 (32%)</td>
<td>30 (81%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>M — 24 (65%)</td>
<td>II — 20 (54%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>III — 1 (3%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>IV — 0 (0%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SarcMTB(false+) (n = 6)</td>
<td>44 (4.7)</td>
<td>F — 2 (33%)</td>
<td>II — 4 (67%)</td>
<td>3 (50%)</td>
<td>2 (33%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>M — 4 (67%)</td>
<td>II — 2 (33%)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

F: female; LS: Löfgren syndrome; M: male; MTB: mycobacterium tuberculosis; S: sarcoidosis; SD: standard deviation

Table 2. Detailed characteristics of sarcoidosis patients with positive culture or BACTEC results from bronchoscopy sample (SarcMTB(+) group)

<table>
<thead>
<tr>
<th>Patient</th>
<th>Gender</th>
<th>Age</th>
<th>X-ray stage at onset</th>
<th>LS at onset</th>
<th>Extra-pulmonary sarcoidosis</th>
<th>Method of MTB assessment</th>
<th>Sarcoidosis activity at V(0)</th>
<th>Anti-TB treatment</th>
<th>Follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>M</td>
<td>45</td>
<td>I</td>
<td>No</td>
<td>Eyes</td>
<td>BACTEC</td>
<td>Inactive</td>
<td>No</td>
<td>Recovery</td>
</tr>
<tr>
<td>2</td>
<td>M</td>
<td>37</td>
<td>I</td>
<td>Yes</td>
<td>No</td>
<td>BACTEC</td>
<td>Inactive</td>
<td>Yes</td>
<td>Recovery</td>
</tr>
<tr>
<td>3</td>
<td>F</td>
<td>41</td>
<td>II</td>
<td>No</td>
<td>No</td>
<td>Culture 3 colonies</td>
<td>Active</td>
<td>Yes</td>
<td>Chronic progressive</td>
</tr>
<tr>
<td>4</td>
<td>M</td>
<td>47</td>
<td>I</td>
<td>Yes</td>
<td>No</td>
<td>BACTEC</td>
<td>Inactive</td>
<td>No</td>
<td>Recovery</td>
</tr>
<tr>
<td>5</td>
<td>F</td>
<td>48</td>
<td>I</td>
<td>Yes</td>
<td>No</td>
<td>Culture 2 colonies</td>
<td>Inactive</td>
<td>Yes</td>
<td>Recovery</td>
</tr>
<tr>
<td>6</td>
<td>M</td>
<td>47</td>
<td>II</td>
<td>No</td>
<td>No</td>
<td>Culture 2 colonies</td>
<td>Active</td>
<td>Yes</td>
<td>Chronic progressive</td>
</tr>
</tbody>
</table>

In patients 2, 3, 5, 6 the decision of anti-TB treatment was made in a consequence of the positive culture or BACTEC result obtained during diagnostic procedures of suspected sarcoidosis. Radiological changes recovered completely in patients 1 and 4 without anti-TB treatment. In patients 3 and 6 radiological changes progressed despite anti TB-treatment; F: female; M: male; TB: tuberculosis

The control group

The control group (n = 37, 17 females) — consisted of inhabitants of Lodz city and Lodz province. The group was composed of healthy volunteers, age-matched to the sarcoidosis group. All subjects completed the questionnaire concerning individual TB history, and the answers to all questions were negative. In all patients, chest X-ray was normal, or in case of abnormal chest X-ray, tuberculosis could be unambiguously excluded. None of these patients were treated with systemic steroids or immunosuppressive drugs, nor suffered any disease connected with depleted immune response. None of the subjects had a positive history of sarcoidosis.

The TB low-risk group

Medical students (n = 21, 6 females) with no history of TB or TB contacts, as assessed by a TB questionnaire. Chest X-ray taken during the last 12 months was normal.

The active TB group

Patients (n = 23, 9 females) actually treated due to lung tuberculosis (between 2nd and 6th week of treatment), with typical clinical and radiological picture and positive sputum or bronchial washing culture results.

Sarcoidosis patients were followed up for at least 2 years (regular every 3–6-month visits in out-patient department and telephone check-ups).

All subjects participating in the study were provided with relevant information, after which they signed the consent. The Ethical Committee at Medical University of Lodz approved the protocol (RNN/110/14/KE).

QuantiFERON-TB GOLD In-tube (QFT) was performed according to the manufacturer’s in-
Table 3. Results of QuantiFERON TB GOLD test in all subgroups — Fisher’s exact test

<table>
<thead>
<tr>
<th>Group</th>
<th>Positive</th>
<th>Negative</th>
<th>All</th>
<th>%</th>
<th>Versus control group (p-value)</th>
<th>Versus low TB risk group (p-value)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SarcMTB(false+)</td>
<td>0</td>
<td>6</td>
<td>6</td>
<td>0</td>
<td>1.0</td>
<td>1.0</td>
</tr>
<tr>
<td>SarcMTB(-)</td>
<td>9</td>
<td>28</td>
<td>37</td>
<td>24.3</td>
<td>0.37</td>
<td>0.08</td>
</tr>
<tr>
<td>Sarc (entire)</td>
<td>9</td>
<td>34</td>
<td>43</td>
<td>20.9</td>
<td>0.56</td>
<td>0.15</td>
</tr>
<tr>
<td>Control</td>
<td>5</td>
<td>32</td>
<td>37</td>
<td>13.5</td>
<td>–</td>
<td>0.4</td>
</tr>
<tr>
<td>TB active</td>
<td>16</td>
<td>7</td>
<td>23</td>
<td>69.6</td>
<td>–</td>
<td>&lt; 0.00001</td>
</tr>
<tr>
<td>Low TB risk</td>
<td>1</td>
<td>20</td>
<td>21</td>
<td>4.8</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

Discussion

In our outcomes, the frequency of latent tuberculosis infection based on QFT results is not significantly higher when compared to age-matched controls. Results obtained by other authors are similar: low incidence of positive results among Danish sarcoidosis patients [11] or high (however, corresponding to high incidence of TB in the studied society) frequency of positive results documented by authors from India [12]. In the study performed by other researchers among Polish, formerly vaccinated sarcoidosis patients, the percentage of positive results was 4.6 when assessed by QFT, and 3.7 when assessed by T-SPOT TB test [13]. Although the percentage of positive outcomes in our sarcoidosis group was slightly higher than in the control group, it well matched the 20.4% prevalence of latent TB reported for Polish blood donors [15]. Therefore, it is justified to say that the frequency of latent TB infection in sarcoidosis patients reflects the one reported in the general population, from which sarcoidosis patients originate.

By using QFT we were able to show negative QFT results in all sarcoidosis patients with highly suspected false positive culture results. Tuberculosis in these patients was recognized as unlikely using similar approach as Fischl et al. [16], therefore using clinical outcome, despite an initial positive culture for M. tuberculosis. Although such approach would be recognized as controversial, careful follow-up justified rightness of our decision. We emphasize that QFT negative result alone cannot be used as a proof of false-negative MTB culture, however, in confrontation with the overall clinical description, it was recognized as potentially useful additional diagnostic information. To the best of our knowledge, this is the first study with the use of QFT in sarcoidosis patients, which also included those with positive culture results.
Among the sarcoidosis group with positive culture results, in all patients, the possibility of TB infection was considered as very low. Therefore, in two of them, the decision to abandon the anti-TB treatment was taken. Both patients with stage I disease were free of symptoms and their chest X-rays were normal at follow-up examination, even though one was treated with systemic steroids for over 12 months due to ocular sarcoidosis. In the remaining two patients with stage I sarcoidosis, the anti-TB treatment was introduced (Pt 5, a primary school teacher — due to potential high epidemiologic threat, and Pt 2, following decision of a pulmonologist representing another center, and his opinion on this matter was not shared by our group). Systemic steroids were applied in 4 patients. In none systemic steroids were introduced prior to obtaining the positive culture/BACTEC results.

As the interpretation, two possibilities should be considered: the occurrence of false negative results of QFT or false positive results of bronchial aspirate culture. The pooled analysis of QFT results from different studies revealed the sensitivity of 80% and specificity of 79% [17]. Also, in other studies, false negative IGRA results are not rare in active TB [18, 19]. At risk are small children with severe TB forms, those with reduced number and function of lymphocytes [20–22], patients in immunosuppression related to different diseases, lower platelet, protein and albumin levels, or senility [19–22]. None of the study subjects presented any of the described conditions. Therefore, false-negative QFT results may not be excluded with full confidence. A second possibility are false positive sputum-culture results for MTB. It is not surprising, as specimen cross-contamination with MTB was reported in many laboratories [6, 23, 24]. A cross-contamination of TB strains was studied in our city by the use of genotyping methods, and was found in 4 out of 98 clustered strains [25]. Taking into consideration all clinical, radiological, and laboratory results, we are convinced of false culture results in all these sarcoidosis patients. The most important features in support of this interpretation and present in our patients in variable constellations, are: predominance of intrathoracic lymph nodes involvement over parenchymal disease (isolated lymphonodal tuberculosis may happen in primary TB only, therefore it is unlikely in adult members of TB vaccinated society), lack of endobronchial changes suggestive of TB, acute onset, complete resolution of radiological changes despite lack of anti-TB treatment, and radiological progression regardless of anti-TB treatment.

Our observations strengthen the suggestion that clinicians should not always confidently repeat clichés, but rather evaluate positive cultures critically, because such approach would allow to decrease the probability of unnecessary treatment and its possible complications.

Sarcoidosis is characterized by enhanced local immunological reactions and consequent peripheral anergy (immunological paradox) [26]. T regulatory cells (CD4+CD25+FOXP3+ and CD4+CD39+) may be involved, as they incompletely control the inflammation of injured tissues, but are powerful enough to mediate peripheral anergy [27, 28]. IGRA performed on whole blood (QFT) or peripheral blood mononuclear cells (T-SPOT TB) could theoretically be negative due to activity of these cells but interestingly, it was shown that n'Treg cells incompletely blocked IFN-gamma and TNF secretion by autologous cells [27]. As several patients of our group with active disease were QFT-positive, the possibility of false negative results due to this phenomenon is unlikely. It is worth noticing that the new version of QFN — QuantiFERON TB Plus accessing in addition to CD4+ T-cell response also CD8+ T-cell response, which can better discriminate active TB from LTBI [29, 30], as well as recent exposure to TB [31] will be especially useful in situation like ours.

One limitation of our study was a small number of sarcoidosis patients with false-positive culture results. Another weakness was lack of sarcoidosis patients with true concurrent TB, which would allow to verify the sensitivity and specificity of QFT in this specific clinical situation. However, such patients are rare, and it seems improbable to recruit satisfactory sample of such subjects.

Conclusion

QFT has been found to be the useful test for the detection of latent TB infection in sarcoidosis patients. In addition, we confirm that sarcoidosis activity does not negatively influence the result of QFT. Moreover, QFT would be proposed as a cost-saving diagnostic test providing additional diagnostic information when false positive MTB culture result in the sarcoidosis patient is highly suspected. However, in each case clinical, radiological and epidemiological data should be considered before taking the therapeutic decision.
Conflict of interest

The authors declare no conflict of interest.

References:


